Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response

NCT03655821 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT03655821
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03655821 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response
Lead sponsor
Radboud University Medical Center
Phase
Phase 4
Overall status
Terminated
Start date
February 1, 2019
Completion date
May 11, 2021
Enrollment
81 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

mesothelioma, non small cell lung cancer